knowledge -WSS

knowledge

author：entertainment 2025-09-29 23:04:11 - browse：51699

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

WSS

What the Wegovy shortage looks like for doctors — and for patients

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

What the Wegovy shortage looks like for doctors — and for patients

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Female surgeons have lower rates of long

Massive project maps cells in human brain in unprecedented detail

knowledge

knowledge

Wikipedia

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

STAT Readout: Today's biotech news includes Sana and Amylyx

Virginia high school admissions case could be legal follow

The Affordable Care Act has saved billions in health care costs

Psychedelics group wrestles with new pharma identity

Why Medicare shouldn’t cover every FDA

Virginia high school admissions case could be legal follow

Biogen walks away from Aduhelm, years after polarizing approval

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Vertex non

Wikipedia

STAT Readout: Today's biotech news includes Sana and Amylyx

How should state employee insurance handle Wegovy?

Better Therapeutics data on benefit with GLP

Zyn nicotine pouches become unlikely player in latest culture war

Researchers CRISPR chickens in bid to protect them from bird flu

White House pharmacy plagued with problems, investigation finds

focus

hotspot

focus

focus